Cytokinetics (CYTK) stock closes up 3.5% into year-end as Myqorzo launch nears, insider sale disclosed
Cytokinetics, Incorporated shares ended Wednesday up 3.5% at $63.54, the final U.S. trading session of 2025, after markets closed Thursday for the New Year’s Day holiday. The stock has traded between $29.31 and $70.98 over the past 52 weeks, according to market data. New York Stock Exchange
